Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Medical Genetics · Lobular Breast Cancer

Does CDH1 Mutation Increase Lobular Breast Cancer Risk?

At a Glance

Yes, testing positive for a CDH1 gene mutation significantly increases the lifetime risk of developing lobular breast cancer to between 37% and 50%. Because this cancer can be hard to detect, carriers require specialized high-risk screening, including annual breast MRIs starting at age 30.

Yes, testing positive for a CDH1 gene mutation significantly increases a woman’s risk of developing breast cancer, specifically a type called lobular breast cancer (or invasive lobular carcinoma) [1][2]. While the CDH1 gene is primarily known for causing Hereditary Diffuse Gastric Cancer (HDGC), individuals with this mutation face a lifetime cumulative risk of lobular breast cancer estimated between 37% and 42%, with some clinical estimates reaching up to 50% [3][4][5].

Managing high risks for two distinct, serious cancers can feel overwhelming, but medical guidelines provide a clear path forward to protect your health. (Note: While clinical guidelines often use the term “women” or “female carriers,” these risks and screening protocols also apply to transgender men and non-binary individuals assigned female at birth who retain breast tissue).

Understanding Lobular Breast Cancer

The CDH1 gene provides instructions for making a protein called E-cadherin, which acts like a microscopic glue that holds cells together. When this gene is mutated, the lack of E-cadherin allows cells to behave and grow abnormally [6][7].

Unlike the more common ductal breast cancer, which typically forms a distinct, firm lump, lobular breast cancer begins in the milk-producing glands (lobules) and tends to grow in single-file lines or sheet-like patterns [6][8]. Because it often does not form a hard lump, it can be more difficult to detect through physical touch or standard 2D mammograms [9]. Furthermore, lobular breast cancers are typically estrogen receptor-positive (ER+), meaning they use hormones to grow [10][11].

Recommended Screening Protocols

Because of the elevated risk and the “stealthy” way lobular breast cancer grows, standard breast cancer screening is not enough. It is strongly recommended that CDH1 mutation carriers follow specialized, high-risk screening protocols [12][13].

These protocols typically involve:

  • Starting Early: Routine surveillance should generally begin at age 30 [4][14]. If you are diagnosed with the mutation after age 30, it is not too late; screening should begin immediately upon discovering the genetic risk [9].
  • Annual Breast MRI: A breast MRI (Magnetic Resonance Imaging) with contrast is crucial because it is significantly better at detecting lobular breast cancer than a standard mammogram [9][15].
  • Annual Mammograms: Mammograms are usually still recommended alongside MRIs [12][16]. Guidelines often recommend 3D mammograms (digital breast tomosynthesis) for high-risk patients because they improve detection rates. Many high-risk programs advise alternating the MRI and the mammogram every six months, so imaging occurs twice a year.
  • Clinical Breast Exams: You should have a physical breast examination performed by a medical professional every 6 to 12 months [12][4].

Options: Surveillance, Medications, and Surgery

If you have researched HDGC, you likely know that preventative stomach removal (prophylactic total gastrectomy) is strongly recommended for CDH1 carriers because diffuse gastric cancer is incredibly difficult to detect early [17][18].

However, breast cancer is managed differently:

  • Surveillance First: Because breast MRI is highly effective at catching breast cancer early, routine preventative breast removal (prophylactic mastectomy) is not the standard medical recommendation for all CDH1 carriers [16][4][19]. Careful, strict surveillance is the preferred clinical path.
  • Risk-Reducing Medications (Chemoprevention): Because these cancers are typically hormone-driven, daily medications (like tamoxifen or aromatase inhibitors) can be used to significantly lower the risk of developing breast cancer [20][21].
  • Prophylactic Surgery: A preventative mastectomy remains a valid option that you can discuss with a multidisciplinary care team [13][14][22]. This may be considered if you have a strong family history of breast cancer, extreme anxiety about screening, or very dense breast tissue. (Breast density is determined during a mammogram and refers to having more fibrous and glandular tissue than fat, which can make tumors harder to see on standard imaging.)

Common questions in this guide

How high is the risk of breast cancer if I have a CDH1 mutation?
Individuals with a CDH1 mutation face an estimated 37% to 50% lifetime risk of developing a specific type of breast cancer known as lobular breast cancer.
Why do I need a breast MRI instead of just a mammogram?
Lobular breast cancer grows in single-file lines or sheet-like patterns rather than forming a distinct, hard lump. A breast MRI with contrast is significantly better at detecting this type of cancer early compared to a standard 2D mammogram.
Do I need a preventative mastectomy if I test positive for CDH1?
Routine preventative breast removal is not the standard recommendation for all CDH1 mutation carriers, as MRIs are highly effective at catching it early. However, a preventative mastectomy remains a valid option, especially if you have dense breast tissue or a strong family history.
Are there medications that can lower my risk of CDH1-related breast cancer?
Yes, because lobular breast cancers are typically driven by hormones, daily medications like tamoxifen or aromatase inhibitors can be prescribed. This strategy, known as chemoprevention, can significantly lower your risk of developing breast cancer.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How dense is my breast tissue based on my past mammograms, and how does that affect the accuracy of my imaging?
  2. 2.Can we coordinate the schedule for my breast MRIs and mammograms with my regular stomach endoscopy screenings to reduce my hospital visits?
  3. 3.Given my specific family history, am I a good candidate for risk-reducing medications (chemoprevention) like tamoxifen or an aromatase inhibitor?
  4. 4.What are the common side effects of chemoprevention, and how would these medications interact with my daily life or other health conditions?
  5. 5.Should I be referred to a specialized high-risk breast clinic or a breast surgical oncologist to manage my surveillance?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can I Choose Endoscopy Over Stomach Removal for HDGC?Did H. pylori Cause My Stomach Cancer?Gastric Cancer Fluid Buildup: How is Ascites Treated?How to Manage Dumping Syndrome After Stomach Surgery?Is Linitis Plastica the Same as Diffuse Gastric Cancer?What Does Claudin 18.2 Positive Mean for Gastric Cancer?What Do Signet Ring Cells Mean in Stomach Cancer?Why Do Stomach Cancer Survivors Need Bone Scans?Why Chemo Before Surgery for Diffuse Gastric Cancer?Why Do Standard Endoscopies Miss Diffuse Gastric Cancer?

References

References (22)
  1. 1

    Prognosis and outcome in CDH1-mutant lobular breast cancer.

    Corso G, Veronesi P, Sacchini V, Galimberti V

    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2018; (27(3)):237-238 doi:10.1097/CEJ.0000000000000405.

    PMID: 29595757
  2. 2

    First report of a Mexican family with mutation in the CDH1 gene.

    Martínez Valenzuela C, Castelán-Maldonado EE, Carvajal-Zarrabal O, Calderón-Garcidueñas AL

    Molecular genetics & genomic medicine 2020; (8(11)):e1208 doi:10.1002/mgg3.1208.

    PMID: 32886433
  3. 3

    Germline CDH1 Variants and Lifetime Cancer Risk.

    Ryan CE, Fasaye GA, Gallanis AF, et al.

    JAMA 2024; (332(9)):722-729 doi:10.1001/jama.2024.10852.

    PMID: 38873722
  4. 4

    Hereditary Diffuse Gastric Cancer Syndrome and the Role of CDH1: A Review.

    Gamble LA, Heller T, Davis JL

    JAMA surgery 2021; (156(4)):387-392 doi:10.1001/jamasurg.2020.6155.

    PMID: 33404644
  5. 5

    Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria.

    Xicola RM, Li S, Rodriguez N, et al.

    Journal of medical genetics 2019; (56(12)):838-843 doi:10.1136/jmedgenet-2019-105991.

    PMID: 31296550
  6. 6

    Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colon.

    Gronewold M, Grote I, Bartels S, et al.

    The journal of pathology. Clinical research 2024; (10(2)):e12361 doi:10.1002/2056-4538.12361.

    PMID: 38618992
  7. 7

    Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.

    Luveta J, Parks RM, Heery DM, et al.

    Oncology and therapy 2020; (8(1)):1-11 doi:10.1007/s40487-019-00105-0.

    PMID: 32700069
  8. 8

    Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.

    De Schepper M, Vincent-Salomon A, Christgen M, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022; (35(12)):1812-1820 doi:10.1038/s41379-022-01135-2.

    PMID: 35922548
  9. 9

    The Breast Cancer Screening and Timing of Breast MRI-Experience in a Genetic High-Risk Screening Clinic in a Comprehensive Cancer Center.

    Wang X, Chang MD, Lee MC, Niell BL

    Current oncology (Toronto, Ont.) 2022; (29(3)):2119-2131 doi:10.3390/curroncol29030171.

    PMID: 35323371
  10. 10

    Breast Cancer Metastasis to the Optic Nerve: A Case Report.

    Zouiten O, Abbassi FZ, Afani L, et al.

    Cureus 2025; (17(9)):e91984 doi:10.7759/cureus.91984.

    PMID: 41080317
  11. 11

    Invasive lobular carcinoma of the breast with multifocal gastrointestinal, ovarian, and peritoneal metastases: a case report.

    Karkeabadi N, Omranipour R, Nozheh A, et al.

    Journal of medical case reports 2026; (20(1)).

    PMID: 41795110
  12. 12

    Hereditary breast cancer: syndromes, tumour pathology and molecular testing.

    Sokolova A, Johnstone KJ, McCart Reed AE, et al.

    Histopathology 2023; (82(1)):70-82 doi:10.1111/his.14808.

    PMID: 36468211
  13. 13

    Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect.

    Corso G, Figueiredo J, La Vecchia C, et al.

    Journal of medical genetics 2018; (55(7)):431-441 doi:10.1136/jmedgenet-2018-105337.

    PMID: 29929997
  14. 14

    [Hereditary diffuse gastric cancer].

    Knipper K, Fuchs HF, Alakus H, et al.

    Chirurgie (Heidelberg, Germany) 2023; (94(5)):400-405 doi:10.1007/s00104-023-01806-z.

    PMID: 36700973
  15. 15

    Hereditary Diffuse Gastric Cancer-Update Based on the Current Consort Recommendations.

    Treese C, Siegmund B, Daum S

    Current oncology (Toronto, Ont.) 2022; (29(4)):2454-2460 doi:10.3390/curroncol29040199.

    PMID: 35448173
  16. 16

    Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.

    Mirandola S, Pellini F, Granuzzo E, et al.

    International journal of surgery case reports 2019; (58()):92-95 doi:10.1016/j.ijscr.2019.03.053.

    PMID: 31028995
  17. 17

    Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer.

    Huynh JM, Laukaitis CM

    Molecular genetics & genomic medicine 2016; (4(2)):232-6 doi:10.1002/mgg3.197.

    PMID: 27064202
  18. 18

    Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients.

    Strong VE, Gholami S, Shah MA, et al.

    Annals of surgery 2017; (266(6)):1006-1012 doi:10.1097/SLA.0000000000002030.

    PMID: 27759617
  19. 19

    Laparoscopic Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer in CDH1 Mutation Carriers.

    Ithurralde-Argerich J, Rosner L, Rizzolo M, et al.

    Journal of laparoendoscopic & advanced surgical techniques. Part A 2021; (31(7)):729-737 doi:10.1089/lap.2021.0239.

    PMID: 34097461
  20. 20

    Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis.

    Alwashmi ASS, Khan NU, Chen T

    Scientific reports 2025; (15(1)):6796 doi:10.1038/s41598-025-89915-z.

    PMID: 40000769
  21. 21

    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Nelson HD, Fu R, Zakher B, et al.

    JAMA 2019; (322(9)):868-886 doi:10.1001/jama.2019.5780.

    PMID: 31479143
  22. 22

    Second-hit CDH1 gene mechanisms in hereditary diffuse gastric and lobular breast cancer syndrome: frequency and impact on tumorigenesis.

    Corso G, Magnoni F, Dal Molin M, et al.

    Human molecular genetics 2025; (34(16)):1345-1352 doi:10.1093/hmg/ddaf092.

    PMID: 40485214

This information about CDH1 and breast cancer risk is for educational purposes only and does not replace professional medical advice. Always consult with a genetic counselor or breast specialist regarding your personal screening needs.

Get notified when new evidence is published on diffuse gastric adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.